SCHEMBL2014359

SCHEMBL2014359

O=C(O)Cc1ccccc1NCC(=O)OCc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
MAPK1 P28482 1/20 0.53
CXCL8 P10145 3/20 0.46
ENPP2 Q13822 1/20 0.45
CAMK2A Q9UQM7 1/20 0.44
PLAU P00749 2/20 0.44
PTGS2 P35354 2/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
AKR1B10 O60218 1/20 0.43
UGT1A9 O60656 1/20 0.43
TRPA1 O75762 1/20 0.43
ABCB11 O95342 1/20 0.43
MT-CO2 P00403 1/20 0.43
TTR P02766 1/20 0.43
ALB P02768 1/20 0.43
UGT1A6 P19224 1/20 0.43
UGT1A1 P22309 1/20 0.43
PTGS1 P23219 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28598894 0.81 ALDH1A1 (0.53) ALDH1A1L3MBTL1MAPK1PLAUNPC1
SCHEMBL15015538 0.80 CXCL8 (0.57) CXCL8CAMK2APTGS2AKR1B10UGT1A9
SCHEMBL8688821 0.79 ALDH1A1 (0.51) ALDH1A1L3MBTL1MAPK1PLAUNPC1
SCHEMBL1163050 0.79 NPC1 (0.64) ALDH1A1CXCL8ENPP2PLAUNPC1
SCHEMBL8053191 0.77 SIRT2 (0.53) ALDH1A1L3MBTL1MAPK1PLAUNPC1
SCHEMBL62534 0.77 ALDH1A1 (0.59) ALDH1A1L3MBTL1MAPK1PLAUKMT2A
SCHEMBL11217423 0.77 HSD17B10 (0.55) ALDH1A1L3MBTL1CXCL8CAMK2APTGS2
SCHEMBL8768501 0.76 CXCL8 (0.57) ALDH1A1CXCL8CAMK2APTGS2AKR1B10
Hydrochloric Acid SCHEMBL27368126 0.75 ALDH1A1 (0.58) ALDH1A1L3MBTL1MAPK1PLAUKMT2A
SCHEMBL20697269 0.75 ALDH1A1 (0.46) ALDH1A1L3MBTL1MAPK1PLAUNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7964730-B2 Amino-substituted ethylamino β2 adrenergic receptor agonists THERAVANCE, INC. (US) 2011-06-21 US disclosed
US-20090111850-A1 Amino-Substituted Ethylamino Beta2 Adrenergic Receptor Agonists THERAVANCE BIOPHARMA R&D IP, LLC 2009-04-30 US disclosed
EP-1687257-B1 AMINO-SUBSTITUTED ETHYLAMINO BETA2 ADRENERGIC RECEPTOR AGONISTS THERAVANCE INC (US) 2009-04-15 EP disclosed
US-7399863-B2 Amino-substituted ethylamino β2 adrenergic receptor agonists THERAVANCE, INC. (US) 2008-07-15 US disclosed
US-20050113411-A1 Amino-substituted ethylamino beta2 adrenergic receptor agonists THERAVANCE BIOPHARMA R&D IP, LLC 2005-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111850-A1 Amino-Substituted Ethylamino Beta2 Adrenergic Receptor Agonists ADRB2, ADRB1, ADRA2A ALDH1A1 989/4885L3MBTL1 3605/4885MAPK1 2640/4885
US-20050113411-A1 Amino-substituted ethylamino beta2 adrenergic receptor agonists ADRB2, ADRB1, ADRA2A ALDH1A1 989/4885L3MBTL1 3605/4885MAPK1 2640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.